TY - JOUR
T1 - Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma
AU - Okamura, Ikue
AU - Imai, Hisao
AU - Mori, Keita
AU - Ogura, Kazuto
AU - Isoda, Atsushi
AU - Mihara, Keichiro
AU - Matsumoto, Morio
AU - Saito, Ryusei
AU - Takahashi, Toshiaki
AU - Ikeda, Takashi
N1 - Publisher Copyright:
© 2014, The Japanese Society of Hematology.
PY - 2014/1
Y1 - 2014/1
N2 - Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare extranodal lymphoma with a 5-year survival rate of 80–95 %. There is no standard treatment strategy for pulmonary MALT lymphoma. In the present study, we performed a retrospective evaluation of systemic rituximab monotherapy (375 mg m−2 day−1, 4–8 cycles) as first-line treatment in patients with pulmonary MALT lymphoma. Of the eight patients enrolled, five achieved complete response, one achieved partial response, and two showed stable disease. Median progression-free survival was 66.0 months (range 9.7–87.2 months). Treatment was well tolerated and all patients were alive during the median follow-up period of 64.0 months. Rituximab monotherapy was efficacious in patients with pulmonary MALT lymphoma, demonstrating long-term disease stabilization and symptom reduction. Larger prospective studies are warranted to further assess the efficacy of rituximab monotherapy. In conclusion, rituximab monotherapy may be considered for first-line therapy in patients with pulmonary MALT lymphoma.
AB - Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare extranodal lymphoma with a 5-year survival rate of 80–95 %. There is no standard treatment strategy for pulmonary MALT lymphoma. In the present study, we performed a retrospective evaluation of systemic rituximab monotherapy (375 mg m−2 day−1, 4–8 cycles) as first-line treatment in patients with pulmonary MALT lymphoma. Of the eight patients enrolled, five achieved complete response, one achieved partial response, and two showed stable disease. Median progression-free survival was 66.0 months (range 9.7–87.2 months). Treatment was well tolerated and all patients were alive during the median follow-up period of 64.0 months. Rituximab monotherapy was efficacious in patients with pulmonary MALT lymphoma, demonstrating long-term disease stabilization and symptom reduction. Larger prospective studies are warranted to further assess the efficacy of rituximab monotherapy. In conclusion, rituximab monotherapy may be considered for first-line therapy in patients with pulmonary MALT lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=84922073738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922073738&partnerID=8YFLogxK
U2 - 10.1007/s12185-014-1694-8
DO - 10.1007/s12185-014-1694-8
M3 - Article
C2 - 25378228
AN - SCOPUS:84922073738
SN - 0925-5710
VL - 101
SP - 46
EP - 51
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 1
ER -